• ICG001: Reframing β-Catenin in Fibrosis

  2026-09-29

  The 2026 biliary atresia study positions MMP7-driven E-cadherin loss and β-catenin nuclear translocation as a mechanistic route to liver fibrosis. This article explains how ICG001, a selective Wnt/β-catenin pathway inhibitor, can test whether CBP-dependent β-catenin transcription is a functionally necessary downstream node in EMT and fibrosis, while also defining practical controls, translational boundaries, and opportunities across oncology and regenerative disease models.

• Digoxin: A PK-Aware Research Design Guide

  2026-09-29

  Digoxin research becomes more reproducible when target engagement, exposure, tissue context, and assay limitations are considered together. This guide connects cardiac glycoside pharmacology with disease-state pharmacokinetic insights and cell-specific chikungunya studies.

• Viral RIPK3 Degradation and Proteasome-Linked Inflammation

  2026-09-28

  Liu et al. identified a cowpox virus protein family that recruits host SCF machinery to ubiquitinate and degrade RIPK3, thereby suppressing necroptosis while shaping viral replication and inflammation. The study combines screening, biochemical validation, viral genetics, and mouse models to connect proteasome-dependent substrate loss with pathogen–host adaptation.

• Sphingosine-1-phosphate: Practical Assay Workflows

  2026-09-28

  Use Sphingosine-1-phosphate to connect receptor activation with early signaling and later cell-fate outcomes—while keeping receptor subtype and cell context in view. This guide translates an intracerebral hemorrhage study into a practical, control-rich workflow for neuronal apoptosis assays and related vascular research.

• Sulfisomidine: Mechanism, Evidence & Research Use

  2026-09-27

  Sulfisomidine, also known as sulfamethin, is a sulfonamide research compound with a class-based bacterial folate-pathway mechanism and a reported secondary effect on human serum paraoxonase 1 (hPON1). Historical pertussis observations and current product specifications inform research context, but neither establishes sulfisomidine as a current treatment or validates an experimental protocol.

• Gramine and the CUL3–MTDH Ferroptosis Axis

  2026-09-26

  A translational perspective on how Gramine connects CUL3–MTDH regulation to ferroptosis in triple-negative breast cancer research—and how to test that mechanism rigorously.

• Safe DNA Gel Stain in RNA Assay Workflows

  2026-09-25

  Safe DNA Gel Stain can make endpoint DNA and RNA gel visualization more compatible with blue-light workflows. This article explains how to interpret gel-based evidence alongside amplification assays—and where stain choice cannot answer a diagnostic question.

• HNRNPU K181 Lactylation Rewires Cervical Cancer Metabolism

  2026-09-25

  A 2026 study identifies lactylation of HNRNPU at K181 as a link between lactate accumulation and PHGDH-dependent serine biosynthesis in cervical cancer. The findings connect a post-translational modification to RNA regulation and tumor metabolism, while suggesting experiments needed to test the pathway’s therapeutic relevance.

• Faropenem Sodium: Potency vs. Renal Disposition

  2026-09-24

  Faropenem sodium is a penem antibiotic with broad antibacterial activity, but its transporter biology raises a separate question: how do researchers distinguish bacterial potency from renal handling? This article interprets the human NPT1 findings and turns them into practical guidance for designing and reading transport assays.

• Safe DNA Gel Stain: Practical Gel Workflow Guide

  2026-09-24

  A scenario-based guide to using Safe DNA Gel Stain (SKU A8743) for DNA and RNA gel visualization, with practical guidance on blue-light imaging, dilution, interpretation, and product selection. It clarifies what gel staining can—and cannot—tell you when evaluating cell viability, proliferation, or cytotoxicity.

• Vardenafil HCl Trihydrate in PDE5 Research

  2026-09-23

  Use Vardenafil HCl Trihydrate to connect quantitative PDE5 inhibition with cGMP-dependent smooth muscle experiments—and to design controls for PDE6 off-target activity. A practical workflow pairs enzyme and tissue assays with the proteoform-aware perspective of recent native mass spectrometry research.

• LEE011 Succinate: CDK Inhibitor Workflows

  2026-09-23

  Build more interpretable cancer research experiments with LEE011 succinate by combining cell proliferation, cell-cycle, and pathway readouts rather than relying on viability alone. This guide also adapts a rigorously tiered assay logic from a recent antiviral study without incorrectly transferring its biology to CDK4/6 research.

• Angiotensin 1/2 (1-6): Assay Workflow Guide

  2026-09-22

  Build reproducible renin-angiotensin system research workflows around the Asp-Arg-Val-Tyr-Ile-His hexapeptide, from solution preparation to receptor-binding assays. The guide also translates recent spike–receptor findings into practical controls while separating established evidence from recommended starting conditions.

• SAN-Plexus Assembloids Model Pacemaker Maturation

  2026-09-22

  This Cell Stem Cell study develops human pluripotent stem cell-derived SAN-plexus assembloids that combine pacemaker, cardiac neural, and atrial-like tissues to model innervation-associated maturation. By integrating electrophysiology with human SAN spatial transcriptomics, the authors identify a CGPO-derived prosaposin–GPR37 signaling axis that promotes pacemaker maturation and provides a framework for studying conduction dysfunction.

• Kitasamycin for Swine Dysentery: Evidence and Limits

  2026-09-21

  The reference study combined isolate-level susceptibility testing, 23S rRNA mutation analysis, and a controlled pig challenge to evaluate kitasamycin for swine dysentery. Its central finding was that prophylactic and therapeutic treatment prevented clinical disease in pigs challenged with a susceptible Brachyspira hyodysenteriae isolate, while widespread macrolide resistance limits general application.

8684 records 1/579 page Next 12345 下5页 Last page